Shanghai Genomics Announces Collaboration on Drug Discovery Project

Shanghai Genomics Inc, the China-based affiliate of GNI has announced an agreement to collaborate on a drug discovery research project with Centocor, Inc.

The collaboration, which will involve biological research aimed at understanding inflammatory signaling pathways, will initially last for a period of one and a half years.

"Shanghai Genomics is delighted to be collaborating with Centocor on this exciting project," said Ying Luo, President and CEO Shanghai Genomics, and President and COO of GNI.

"This is yet another validation of the model we have refined with GNI, where we are the first company to combine innovative Western science with cost-efficient research capabilities in China, and access to the Chinese and Japanese pharmaceutical markets."

Shanghai Genomics will use its expertise in protein purification and cell-based interaction assays to explore receptor protein interactions and intracellular signaling cascades with Centocor. In particular, the research will focus upon the areas of inflammation and oncology.

Utilizing its technology platform, Shanghai Genomics has entered into and completed many research based collaborations with international partners such as Centocor.

Research based collaborations with international partners form a crucial pillar of Shanghai Genomics' business and complement the drug discovery work the company conducts with GNI.